Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
Financial Resilience | Labcorp's robust Q2 performance and raised revenue guidance signal strong financial health and growth potential in the competitive life sciences secto |
Leadership Transition | Explore the impact of new CFO Julia Wang's diverse experience on Labcorp's strategic financial decisions and growth initiatives |
Market Positioning | Delve into Labcorp's $19.7B market cap and its ability to outperform the S&P500, reflecting its competitive strength in diagnostics and life sciences |
Future Prospects | Analysts project EPS growth to 15.54 by FY2026, with a price target of $249, balancing acquisition challenges against potential market expansion opportunities |
Metrics to compare | LH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLHPeersSector | |
---|---|---|---|---|
P/E Ratio | 46.6x | 22.1x | −0.6x | |
PEG Ratio | −1.49 | −0.05 | 0.00 | |
Price/Book | 2.5x | 1.7x | 2.6x | |
Price / LTM Sales | 1.6x | 1.5x | 3.1x | |
Upside (Analyst Target) | 10.7% | 24.0% | 51.5% | |
Fair Value Upside | Unlock | 7.2% | 7.6% | Unlock |